CAR and TCR Form Individual Signaling Synapses and Do Not Cross-activate, However, Can Co-operate in T Cell Activation
Overview
Authors
Affiliations
In engineered T cells the CAR is co-expressed along with the physiological TCR/CD3 complex, both utilizing the same downstream signaling machinery for T cell activation. It is unresolved whether CAR-mediated T cell activation depends on the presence of the TCR and whether CAR and TCR mutually cross-activate upon engaging their respective antigen. Here we demonstrate that the CD3ζ CAR level was independent of the TCR associated CD3ζ and could not replace CD3ζ to rescue the TCR complex in CD3ζ KO T cells. Upon activation, the CAR did not induce phosphorylation of TCR associated CD3ζ and, vice versa, TCR activation did not induce CAR CD3ζ phosphorylation. Consequently, CAR and TCR did not cross-signal to trigger T cell effector functions. On the membrane level, TCR and CAR formed separate synapses upon antigen engagement as revealed by total internal reflection fluorescence (TIRF) and fast AiryScan microscopy. Upon engaging their respective antigen, however, CAR and TCR could co-operate in triggering effector functions through combinatorial signaling allowing logic "AND" gating in target recognition. Data also imply that tonic TCR signaling can support CAR-mediated T cell activation emphasizing the potential relevance of the endogenous TCR for maintaining T cell capacities in the long-term.
Effectors of the Future: Universal Chimeric Antigen Receptor.
Schlegel L, Schlegel P Transfus Med Hemother. 2025; 52(1):61-76.
PMID: 39944409 PMC: 11813278. DOI: 10.1159/000539609.
Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen.
Chih Y, Dietsch A, Koopmann P, Ma X, Agardy D, Zhao B Nat Commun. 2025; 16(1):1262.
PMID: 39893177 PMC: 11787355. DOI: 10.1038/s41467-025-56547-w.
TMX1, a disulfide oxidoreductase, is necessary for T cell function through regulation of CD3ζ.
Chai T, Loh K, Weissman I bioRxiv. 2024; .
PMID: 39386445 PMC: 11463681. DOI: 10.1101/2024.09.22.614388.
Arming Vδ2 T Cells with Chimeric Antigen Receptors to Combat Cancer.
Thomas P, Paris P, Pecqueur C Clin Cancer Res. 2024; 30(15):3105-3116.
PMID: 38747974 PMC: 11292201. DOI: 10.1158/1078-0432.CCR-23-3495.
Integration of ζ-deficient CARs into the CD3ζ gene conveys potent cytotoxicity in T and NK cells.
Kath J, Franke C, Drosdek V, Du W, Glaser V, Fuster-Garcia C Blood. 2024; 143(25):2599-2611.
PMID: 38493479 PMC: 11196866. DOI: 10.1182/blood.2023020973.